Key result
Mesalazine triggers recurrent myopericarditis in ulcerative colitis, resolving after drug cessation.
Why the study?
Mesalazine, a common treatment for inflammatory bowel disease, can rarely cause myopericarditis, but recurrent cases are not well documented.
Case Report (n=1)
Highlights a rare case of recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis, confirmed by dechallenge and rechallenge.
Answers are grounded in this paper and cite their sources.
May prompt consideration of mesalazine as a cause of recurrent myopericarditis in ulcerative colitis; hypothesis-generating and requires confirmation.
Mesalazine is a common treatment for inflammatory bowel disease and can be rarely associated with myopericarditis. We report a case of a 19-year-old man recently diagnosed with ulcerative colitis and started on mesalazine, who presented with chest pain 2 weeks after beginning this therapy. Blood tests demonstrated elevated troponin I. ECG and echocardiographic changes were consistent with myopericarditis. When mesalazine was reintroduced 2 weeks after discharge, he suffered from myopericarditis again. On cessation of the drug, the cardiac symptoms resolved in combination with anti-inflammatory therapy. The onset of symptoms after mesalazine, and improvement of chest pain and cardiac biomarkers after discontinuing the drug, suggest that our patient suffered from a rare drug-hypersensitivity reaction to mesalazine.
No takes yet. Share an insight, caveat, or question.
Dias et al. (2019) conducted a case report in Ulcerative colitis (n=1). Mesalazine was evaluated on Development of myopericarditis. Mesalazine therapy in a 19-year-old man with ulcerative colitis induced recurrent myopericarditis, which resolved upon cessation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: